Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Neurology|February 1, 1987
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's diseaseJ M Cedarbaum, L Breck, H Kutt, et al.
Clinical Neuropharmacology|April 1, 1988
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's diseaseJ M Cedarbaum, M Hoey, H Kutt, et al.
Psychopharmacology|March 16, 1977
Effects of clonidine on habituation and sensitization of acoustic startle in normal, decerebrate and locus coeruleus lesioned ratsM Davis, J M Cedarbaum, G K Aghajanian, et al.
Clinical Neuropharmacology|February 1, 1990
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's diseaseJ M Cedarbaum, M Silvestri, M Clark, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1990
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulationJ M Cedarbaum, M Clark, L H Toy, et al.
Neurosurgery|January 1, 1997
Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)R D Penn, J S Kroin, M M York, et al.
Clinical Neuropharmacology|January 1, 1986
Effect of supplemental carbidopa on bioavailability of L-dopaJ M Cedarbaum, H Kutt, A K Dhar, et al.
The Journal of the American Paraplegia Society|October 1, 1992
Clinical and pharmacokinetic aspects of high dose oral baclofen therapyM L Aisen, M A Dietz, P Rossi, et al.
Experimental Neurology|November 1, 1993
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's diseaseR M Lindsay, C A Altar, J M Cedarbaum, et al.
Brain Research|December 8, 1987
The physiological identification of pyramidal tract neurons within transplants in the rostral cortex taken from the occipital cortex during developmentL L Porter, J M Cedarbaum, D D O'Leary, et al.
Pageof 5